

Subst B3
2. (amended) The [Peptide] peptide according to claim 1, wherein said original amino acid at position 2, Threonine, is substituted by a replacement amino acid selected from the group consisting of Isoleucine, Leucine [or] and Valine.

3. (amended) The [Peptide] peptide according to [any of claims 1-2] claim 2, wherein said original amino acid at position 8, Glutamine, is substituted by replacement amino acid, Alanine.

2B34
4. (amended) The [Peptide] peptide according to [any claims 1-3] Claim 1, [characterized in that it] wherein said peptide comprises the amino-acid sequence of SEQ.ID.[No.:#2-8] NO: 2.

5. (amended) A [Nucleotide sequence characterized in that it] nucleic acid which comprises:

a nucleotide sequence encoding [the] a peptide according to [any of claims 1-4]

Claim 1.

6. (amended) A ^{vaccine} [Vaccine, characterized in that it] which comprises [the] a peptide according to [any of claims 1-4] Claim 1 or an epitope thereof or [the] a nucleotide sequence [according to claim 5] encoding said peptide.

7. (amended) The [Vaccine] vaccine according to claim 6, [characterized in that the] wherein said peptide is mixed with a pharmaceutically acceptable carrier or diluent.

8. (amended) The [Vaccine] vaccine according to [any of claims 6-7] Claim 6, wherein [characterized in that it comprises] an antigen presenting cell[, which] has been preloaded with [the] said peptide.

9. (amended) A [Vaccine] vaccine[, characterized in that it] which comprises:

[the] a T cell receptor against [the peptides] a peptide according to [any of claims 1-4] Claim 1 or cells expressing said T cell receptor.

10. (amended) The [Vaccine] vaccine according to any of claims 6-9, [characterized in that it also] which further comprises one or more compounds selected from the group consisting of an adjuvant, one or more cytokines, antibodies directed against CD2,

CD3, CD27, CD28 or other T cell surface antigens and helper epitopes [to] which stimulate CD4+ or CD8+ T cells.

11. A [Method] method for [the generation of] isolating melanoma antigen reactive tumor infiltrating lymphocytes, [characterized in that it comprises] said method comprising the steps of:

- a. taking a sample of a melanoma from a patient;
- b. isolating [the] tumor infiltrating lymphocytes from [the] said sample;
- c. reacting said tumor infiltrating lymphocytes with [the peptides according to any of claims 1-4] a peptide according to Claim 1 to form an antigen-lymphocyte complex;
- d. [isolating the] recovering lymphocytes [binding to] from said antigen-lymphocyte complex whereby isolated melanoma antigen reactive tumor infiltrating lymphocytes are obtained.

12. (amended) Tumor infiltrating lymphocytes [characterized in that they are capable of binding to the peptides according to any of claims 1-4] which bind to a peptide according to Claim 1.

13. (amended) A [Vaccine characterized in that it] vaccine which comprises tumor infiltrating lymphocytes according to claim 12.

14. (amended) A [Conjugate] conjugate of a peptide according to Claim 1 and a detectable marker[, characterized in that the peptide according to any of claims 1-4].

15. (amended) The [Conjugate] conjugate according to claim 14, [characterized in that the] wherein said detectable marker is a radionuclide.

16. (amended) An [Antibody, characterized in] antibody that it is directed to [the] a peptide according to [claims 1-4] Claim 1.

17. (amended) A [Vaccine, characterized in that it] vaccine which comprises [the] an antibody according to claim 16.

18. (amended) A [Method] method for monitoring progress of immunotherapy in a patient, [characterized in that the] said method comprising: